Camarda Financial Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-20,494
| Closed | -$1.31M | – | 66 |
|
|
2023
Q2 | $1.31M | Buy |
20,494
+803
| +4% | +$53.8K | 0.65% | 51 |
|
|
2023
Q1 | $1.36M | Buy |
19,691
+6,497
| +49% | +$458K | 1.02% | 30 |
|
|
2022
Q4 | $949K | Buy |
13,194
+4,377
| +50% | +$330K | 0.96% | 36 |
|
|
2022
Q3 | $627K | Buy |
8,817
+459
| +5% | +$33.3K | 0.74% | 25 |
|
|
2022
Q2 | $644K | Sell |
8,358
-11,993
| -59% | -$913K | 0.64% | 30 |
|
|
2022
Q1 | $1.49M | Buy |
+20,351
| New | +$1.37M | 0.71% | 37 |
|
|
2021
Q1 | – | Sell |
-21,261
| Closed | -$1.32M | – | 86 |
|
|
2020
Q4 | $1.32M | Hold |
21,261
| – | – | 1.11% | 18 |
|
|
2020
Q3 | $1.28M | Hold |
21,261
| – | – | 1.56% | 16 |
|
|
2020
Q2 | $1.25M | Buy |
21,261
+7,120
| +50% | +$426K | 1.75% | 15 |
|
|
2020
Q1 | $788K | Hold |
14,141
| – | – | 3.98% | 12 |
|
|
2019
Q4 | $908K | Sell |
14,141
-7,120
| -33% | -$408K | 1.93% | 22 |
|
|
2019
Q3 | $1.08M | Hold |
21,261
| – | – | 2.51% | 22 |
|
|
2019
Q2 | $964K | Hold |
21,261
| – | – | 1.89% | 22 |
|
|
2019
Q1 | $1.01M | Hold |
21,261
| – | – | 1.94% | 19 |
|
|
2018
Q4 | $1.1M | Sell |
21,261
-870
| -4% | -$46.7K | 1.31% | 23 |
|
|
2018
Q3 | $1.37M | Buy |
22,131
+600
| +3% | +$35.6K | 1.56% | 13 |
|
|
2018
Q2 | $1.19M | Hold |
21,531
| – | – | 1.25% | 14 |
|
|
2018
Q1 | $1.36M | Sell |
21,531
-100
| -0.5% | -$6.43K | 1.41% | 16 |
|
|
2017
Q4 | $1.33M | Buy |
21,631
+270
| +1% | +$16.9K | 1.59% | 21 |
|
|
2017
Q3 | $1.36M | Hold |
21,361
| – | – | 1.46% | 26 |
|
|
2017
Q2 | $1.19M | Sell |
21,361
-11
| -0.1% | -$599 | 1.27% | 24 |
|
|
2017
Q1 | $1.16M | Hold |
21,372
| – | – | 1.13% | 29 |
|
|
2016
Q4 | $1.25M | Hold |
21,372
| – | – | 0.85% | 54 |
|
|
2016
Q3 | $1.15M | Sell |
21,372
-111
| -0.5% | -$7.13K | 0.7% | 65 |
|
|
2016
Q2 | $1.58M | Hold |
21,483
| – | – | 1% | 32 |
|
|
2016
Q1 | $1.37M | Buy |
21,483
+222
| +1% | +$14K | 0.85% | 33 |
|
|
2015
Q4 | $1.46M | Hold |
21,261
| – | – | 0.9% | 33 |
|
|
2015
Q3 | $1.26M | Hold |
21,261
| – | – | 0.78% | 45 |
|
|
2015
Q2 | $1.42M | Hold |
21,261
| – | – | 0.79% | 40 |
|
|
2015
Q1 | $1.37M | Hold |
21,261
| – | – | 0.76% | 40 |
|
|
2014
Q4 | $1.25M | Hold |
21,261
| – | – | 0.8% | 41 |
|
|
2014
Q3 | $1.09M | Hold |
21,261
| – | – | 0.75% | 41 |
|
|
2014
Q2 | $1.03M | Buy |
+21,261
| New | +$1.05M | 0.71% | 42 |
|
Other funds holding BMY
Camarda Financial Advisors's BMY Position: Q3 2023 in Review
Camarda Financial Advisors sold out of Bristol-Myers Squibb (BMY) in Q3 2023, closing a stake of 20,494 shares — an estimated $1.31M sold.
Camarda Financial Advisors first reported a position in BMY in Q2 2014 and held it in 33 quarters. The position peaked at $1.58M in Q2 2016. 2,387 funds tracked by Wall St. Rank hold BMY as of Q3 2023.
- Camarda Financial Advisors reported no remaining Bristol-Myers Squibb position as of Q3 2023 after selling out during the quarter.
- Camarda Financial Advisors sold 20,494 Bristol-Myers Squibb shares in Q3 2023, an estimated $1.31M.
- Camarda Financial Advisors first reported a position in Bristol-Myers Squibb in Q2 2014 and held it in 33 quarters.
- Camarda Financial Advisors's Bristol-Myers Squibb position peaked at $1.58M in Q2 2016.
- 2,387 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2023.
Based on Camarda Financial Advisors's 13F filing for Q3 2023, filed 15 Nov 2023.